Brief: Catalyst Pharmaceuticals To License North American Rights To Vamorolone For Duchenne Muscular Dystrophy From Santhera Pharmaceuticals

Catalyst Pharmaceuticals

20/06/2023 11:26

June 20 (Reuters) - Catalyst Pharmaceuticals Inc
 CPRX.O :
    * CATALYST PHARMACEUTICALS TO LICENSE NORTH AMERICAN RIGHTS
TO
VAMOROLONE FOR DUCHENNE MUSCULAR DYSTROPHY FROM SANTHERA
PHARMACEUTICALS
    * CATALYST PHARMACEUTICALS INC - VAMOROLONE IS CURRENTLY
UNDER
REVIEW WITH FDA (PDUFA DATE OF OCTOBER 26
    * CATALYST PHARMACEUTICALS INC - EXPECTS TO LAUNCH
VAMOROLONE IN
U.S. EARLY IN Q1 2024
    * CATALYST PHARMACEUTICALS - AGREEMENT TO INCLUDE COMMERCIAL
AND
FUTURE DEVELOPMENT RIGHTS FOR VAMOROLONE FOR ADDITIONAL
INDICATIONS IN NORTH AMERICA
    * CATALYST PHARMACEUTICALS INC - CATALYST WILL MAKE A $75
MILLION
UPFRONT PAYMENT TO SANTHERA
    * CATALYST PHARMACEUTICALS INC - AGREEMENT IS STRUCTURED AS
AN
ALL-CASH TRANSACTION WITH NO FINANCING CONTINGENCIES

Source text for Eikon:  ID:nGNX1Z42Nx 
Further company coverage:  CPRX.O 

 ((reuters.briefs@thomsonreuters.com;))